Abstract: |
AIM: To explore the feasibility of transferring dihydrofolate reductase-(DHFR) gene and cytidine deaminase (CD) fusion gene into mouse bone marrow (BM) cells to induce resistance to high dose methotrexate (MTX) and cytosine arabinoside (Ara-C), and to improve the tolerance of myelosuppression following combination chemotherapy. METHODS: Human double-mutant DHFR-CD fusion gene was transferred into mouse BM cells by retroviral vector Granulocyte-macrophage colony-forming unit (CFU-GM) assay was performed for retrovirally infected and drug treated mouse BM cells. DNA was extracted from mouse BM, and the expression of drug resistant genes was examined by PCR. RESULTS: Drug resistant colonies were formed by donor mouse BM cells co-cultured with the retrovirus producing cells, as well as the BM cells from recipient mice transplanted with the fusion gene transfected BM cells (CFU-GM of donor mice was 14%, χ 2 = 42.55, P<0.01; CFU-GM of recipient mice was 20%, χ 2 = 44.26, P<0.01). The drug resistance to both MTX and Ara-C was also increased in the recipient mice. The survival rate of gene transferred mice was significantly higher compared with the control mice χ 2 = 7.42, P<0.01. Expression of the DHFR-CD fusion gene in the transfected mice was confirmed by PCR. CONCLUSION: Double drug resistant genes can be integrated and expressed in mouse bone marrow cells; furthermore, they can increase the drug resistance to MTX and Ara-C. |